The United Kingdom and the United States have forged a landmark trade agreement that will keep zero tariffs on British pharmaceutical shipments entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This commitment secures that duties on these key exports will stay at nothing for a timeframe of the next three years.
This agreement comes after recent warnings to hike tariffs on patented pharmaceutical products, with figures mentioned reaching 100%.
"This deal between the Britain bolsters the global environment for innovative medicines and introduces much-needed balance to American-British drug exports," an announcement said.
Commercial Significance
Medicines represent one of the the United Kingdom's largest exports to the America, which is clearly the primary buyer for large UK drugmakers.
Export figures indicate that in the year to the end of September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This amount made up 17.4% of British export trade in that period.
"This agreement secures employment, stimulates funding and facilitates the UK to emerge as a global hub for medical research," a government official commented.
Detailed UK Commitments
The pact involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to double total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum drug companies must pay back to the NHS to prevent overspending will be capped at 15%. Last year, rebates were more than 20%.
Recent Tensions
The deal follows a long-running dispute between the drug companies and the British authorities over spending levels and NHS adoption.
The disagreement were heightened by arguments that US consumers were charged significantly more for the same drugs than people in the other developed nations.
Recently, several large manufacturing plans in the UK have been delayed or abandoned, while substantial investments have been directed toward US facilities.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the last ten years.
